Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > May 27, 2024
Daily News
May 27, 2024
- MHLW Panel OKs Avigan for SFTS with Strings Attached, Shionogi COVID Jab Only for Primary Use
May 27, 2024
- Sawai Recalls Antibiotic Cefdinir Manufactured by Choseido, 4 Other APIs
May 27, 2024
- MSD Chief Urges Further Reform around Spillovers; Japan Sales Up 11% in 2023
May 27, 2024
- Choseido Violates GMP Once Again with Cefdinir, More Cases Being Probed
May 27, 2024
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…